GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Inventories, Raw Materials & Components

Contineum Therapeutics (Contineum Therapeutics) Inventories, Raw Materials & Components : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Inventories, Raw Materials & Components?

Contineum Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2024 was $0.00 Mil.


Contineum Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Contineum Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Inventories, Raw Materials & Components Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial - - - - -

Contineum Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus